Abstract：【Objective】To explore the expression and clinical significance of GATA binding protein 3 (GATA3) in cervical cancer and precancerous lesions. 【Methods】A total of 162 cases of cervical surgery specimens admitted to our hospital were collected,including 35 cases of cervical intraepithelial neoplasia (CIN) Ⅰ (the CIN Ⅰ group),43 cases of CIN Ⅱ~Ⅲ (the CIN Ⅱ~Ⅲ group),42 cases of cervical cancer (the cervical cancer group) and 42 cases of normal cervix (the control group). The clinical data and GATA3 mRNA expression levels of the four groups were compared. The clinical data of patients with cervical cancer group and precancerous lesion group (CINⅠ and CINⅡ~Ⅲ) were compared with the other groups. Logistic multivariate regression was analyzed the risk factors affecting cervical cancer. Receiver operating characteristic curve (ROC) and the area under the curve (AUC) were drawn to evaluate the diagnostic efficacy of GATA3 mRNA levels for cervical cancer. 【Results】There were statistically significant differences in GATA3 mRNA among the four groups(P<0.05). GATA3 mRNA in the CINⅠ,CINⅡ~Ⅲ,and cervical cancer groups were all lower than those in the control group (P<0.05). GATA3 mRNA level in the cervical cancer group was lower in that in the CIN Ⅰ group and CIN Ⅱ~Ⅲ group (P<0.05). GATA3 mRNA level in the CIN Ⅱ~Ⅲ group was lower than that in the CIN Ⅰ group (P<0.05). The number of births,the percentage of smoking history,proportion of family history of cervical cancer,and the percentage of sexual partners≥2 in the cervical cancer group were higher than those in the precancerous lesion group (P<0.05),while the age of first sex,age of first childbearing and GATA3 mRNA were lower (P<0.05) . Logistic multivariate analysis showed that the number of births,sex partners≥2 and GATA3 mRNA were all risk factors affecting cervical cancer ( P<0.05). ROC analysis showed that the best cut-off point of GATA3 mRNA expression in cervical tissues for predicting the occurrence of cervical cancer was 1.12,and the sensitivity,specificity and AUC were 80.95%,83.33%,and 0.869,respectively. 【Conclusion】The expression of GATA3 mRNA in cervical cancer and precancerous lesions is abnormally low,and its diagnostic efficiency for cervical cancer is relatively high. It can be used as an important reference index for clinical diagnosis of cervical cancer.
段蓓, 王敏, 徐炜炜. GATA结合蛋白3在宫颈癌及癌前病变组织中的表达及其临床意义[J]. 医学临床研究, 2022, 39(8): 1209-1212.
DUAN Pei, WANG Min, XU Wei-wei. Expression and Clinical Significance of GATA Binding Protein 3 in Cervical Cancer and Precancerous Lesions. JOURNAL OF CLINICAL RESEARCH, 2022, 39(8): 1209-1212.
[1] REVATHIDEVI S,MURUGAN A K,NAKAOKA H,et al.APOBEC:A molecular driver in cervical cancer pathogenesis[J].Cancer Lett,2021,496(25):104-116. [2] STUMBAR S E,STEVENS M,FELD Z. Cervical cancer and its precursors:a preventative approach to screening,diagnosis,and management[J].Prim Care,2019,46(1):117-134. [3] 郭兆坤,蒋英,邓可衡,等. GATA结合蛋白3在肾母细胞瘤组织的表达及其临床意义[J].中华实验外科杂志,2018,35(3):561-563. [4] BAI F,ZHANG L H,LIU X,et al. GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer[J].Theranostics,2021,11(17):8218-8233. [5] 张为远,吴玉梅. 宫颈病变与宫颈癌[M].北京:人民卫生出版社,2012:36-38. [6] 郑英. 宫颈病变三阶梯诊断技术[M]. 郑州:河南科学技术出版社,2011:25-27. [7] JOHNSON C A,JAMES D,MARZAN A,et al. Cervical cancer:an overview of pathophysiology and management[J].Semin Oncol Nurs,2019,35(2):166-174. [8] BEHAREE N,SHI Z,WU D,et al. Diagnosis and treatment of cervical cancer in pregnant women[J].Cancer Med,2019,8(12):5425-5430. [9] BEDELL S L,GOLDSTEIN L S,GOLDSTEIN A R,et al. Cervical cancer screening:past,present,and future[J].Sex Med Rev,2020,8(1):28-37. [10] LAURENT E,BEGUERET H,BONHOMME B,et al. SOX10,GATA3,GCDFP15,androgen receptor,and mammaglobin for the differential diagnosis between triple-negative breast cancer and TTF1-negative lung adenocarcinoma[J].Am J Surg Pathol,2019,43(3):293-302. [11] OLUSLA P,BANERJEE H N,PHILLEY J V,et al. Human papilloma virus-associated cervical cancer and health disparities[J].Cells,2019,8(6):36-39. [12] PIMPLE S A,MISHRA G A. Global strategies for cervical cancer prevention and screening[J].Minerva Ginecol,2019,71(4):313-320.
2022, Vol. 39 
